PPARG and neoplasm: In addition to this regulatory mechanism, off-target side effects of the first generations of PPARγ-agonists even resulted in an increased proliferation rate of tumour and vascular cells, as they involve PPARγ-receptor independent (“non-genomic”) activation of RAS19 and phosphoinositide 3-kinase (PI3K)20 signalling, especially at higher dosages.